BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30124600)

  • 1. Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres.
    Badiyan S; Bhooshan N; Chuong MD; Sharma N; Akhter N; Etezadi V; Hausner P; Kudryasheva S; Kaiser A; Becker S; Guerrero M; Yi BY
    Nucl Med Commun; 2018 Oct; 39(10):915-920. PubMed ID: 30124600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Flamen P; Vanderlinden B; Delatte P; Ghanem G; Ameye L; Van Den Eynde M; Hendlisz A
    Phys Med Biol; 2008 Nov; 53(22):6591-603. PubMed ID: 18978442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment tumor volume as a prognostic factor in metastatic colorectal cancer treated with selective internal radiation to the liver using yttrium-90 resin microspheres.
    Bhooshan N; Sharma NK; Badiyan S; Kaiser A; Moeslein FM; Kwok Y; Amin PP; Kudryasheva S; Chuong MD
    J Gastrointest Oncol; 2016 Dec; 7(6):931-937. PubMed ID: 28078116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
    Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
    Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT).
    Beuzit L; Edeline J; Brun V; Ronot M; Guillygomarc'h A; Boudjema K; Gandon Y; Garin E; Rolland Y
    Eur J Radiol; 2016 Aug; 85(8):1445-52. PubMed ID: 27423686
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kurilova I; Beets-Tan RGH; Ulaner GA; Boas FE; Petre EN; Yarmohammadi H; Ziv E; Deipolyi AR; Brody LA; Gonen M; Sofocleous CT
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1419-1427. PubMed ID: 29766239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK.
    Pennington B; Akehurst R; Wasan H; Sangro B; Kennedy AS; Sennfält K; Bester L
    J Med Econ; 2015; 18(10):797-804. PubMed ID: 25941769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy.
    Schmeel FC; Simon B; Sabet A; Luetkens JA; Träber F; Schmeel LC; Ezziddin S; Schild HH; Hadizadeh DR
    Eur Radiol; 2017 Mar; 27(3):966-975. PubMed ID: 27271923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases.
    Stubbs RS; Cannan RJ; Mitchell AW
    J Gastrointest Surg; 2001; 5(3):294-302. PubMed ID: 11360053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
    Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
    J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 15. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.
    Pardo F; Sangro B; Lee RC; Manas D; Jeyarajah R; Donckier V; Maleux G; Pinna AD; Bester L; Morris DL; Iannitti D; Chow PK; Stubbs R; Gow PJ; Masi G; Fisher KT; Lau WY; Kouladouros K; Katsanos G; Ercolani G; Rotellar F; Bilbao JI; Schoen M
    Ann Surg Oncol; 2017 Sep; 24(9):2465-2473. PubMed ID: 28653161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
    Lau WY; Kennedy AS; Kim YH; Lai HK; Lee RC; Leung TW; Liu CS; Salem R; Sangro B; Shuter B; Wang SC
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):401-7. PubMed ID: 20950954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.
    Tochetto SM; Töre HG; Chalian H; Yaghmai V
    AJR Am J Roentgenol; 2012 May; 198(5):1093-9. PubMed ID: 22528898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.
    Turkmen C; Ucar A; Poyanli A; Vatankulu B; Ozkan G; Basaran M; Serin K; Sanli Y; Adalet I
    Cancer Biother Radiopharm; 2013 Sep; 28(7):534-40. PubMed ID: 23647219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.